FDA Approves Oveporexton, First Orexin Receptor Agonist for Narcolepsy Type 1

The FDA has approved oveporexton (ORZEYFUL), the first orexin receptor agonist indicated for the full symptom burden of narcolepsy type 1—a milestone that clinicians treating this underserved population are likely to note given the limited mechanistic novelty of existing therapies.

The U.S. Food and Drug Administration approved oveporexton (ORZEYFUL; Takeda) on August 5, 2026, for the treatment of narcolepsy type 1 (NT1) in adults, making it the first oral orexin receptor 2 (OX2R) agonist to reach the U.S. market for this indication. Unlike currently available agents, which address individual symptoms such as excessive daytime sleepiness or cataplexy through downstream mechanisms, oveporexton is designed to correct the underlying orexin signaling deficit that defines NT1's pathophysiology.

"Until now, people have managed narcolepsy type 1 with treatments that target symptom relief," said Dr. Emmanuel Mignot, M.D., Ph.D., principal U.S. investigator in the ORZEYFUL Phase 3 program. "As the first and only approved orexin therapy to treat the broad spectrum of the disease, ORZEYFUL can enable a different kind of conversation in the doctor's office about treatment options."

Regulatory Pathway and Clinical Program

The FDA accepted Takeda's new drug application (NDA) for oveporexton in February 2026 and granted Priority Review, reflecting the unmet need in NT1. The approval rests on data from two global Phase 3 trials—FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002)—both enrolling adult patients with NT1. According to the press release, both studies demonstrated statistically significant improvements across excessive daytime sleepiness, cataplexy frequency, and health-related quality of life. Evaluated doses included oveporexton 1 mg twice daily and 2 mg twice daily.

The safety profile across pooled Phase 3 data warrants careful attention. Insomnia emerged as a prominent adverse effect, occurring in 55% and 60% of patients receiving 1 mg and 2 mg twice-daily dosing, respectively, compared with 1% in the placebo group. Urinary frequency was reported in 53% and 58% of the same respective dose groups versus 5% with placebo, and urinary urgency occurred in 15%–16% of treated patients versus 1% with placebo—findings attributed to OX2R agonism on central micturition pathways. Salivary hypersecretion was also reported. Asymptomatic creatine phosphokinase (CPK) elevations greater than 5 times the upper limit of normal were observed in 11% of oveporexton-treated patients versus 5% with placebo; two patients with markedly elevated CPK and transaminase levels discontinued treatment, though no cases involved myoglobinuria or renal impairment.

Oveporexton is contraindicated with strong CYP3A inhibitors, and its use should be approached cautiously with moderate CYP3A inhibitors or inducers. The drug should be avoided in patients with severe hepatic impairment (Child-Pugh C) or severe renal impairment requiring dialysis.

Disease Burden and Current Treatment Landscape

NT1 is a rare, chronic neurological disorder affecting an estimated 120,000 adults in the United States.¹ The condition is characterized by irreversible loss of hypothalamic orexin (hypocretin)-producing neurons, resulting in excessive daytime sleepiness, cataplexy, disrupted nocturnal sleep, and cognitive impairment.² Prior to this approval, management relied principally on wake-promoting agents such as modafinil and solriamfetol, sodium oxybate formulations for cataplexy and sleep consolidation, and older stimulants—none of which restore orexin signaling.³

Mechanism and Drug-Class Context

Oveporexton selectively stimulates OX2R to restore downstream orexinergic signaling implicated in wakefulness regulation and REM-sleep suppression. By acting at the receptor level, the drug addresses the core neurochemical deficit of NT1 rather than compensating for it through alternative arousal pathways. Takeda has also received approval for oveporexton in China and is investigating additional orexin agonists—TAK-360 for NT1, narcolepsy type 2, and idiopathic hypersomnia, and TAK-495—underscoring orexin receptor modulation as an emerging therapeutic class.⁴

Availability and Next Steps

Commercial availability remains pending a DEA controlled substance scheduling determination, expected within 90 days of approval. Distribution will occur through specialty pharmacy channels. The high rates of insomnia and lower urinary tract symptoms observed in Phase 3 trials—substantially exceeding placebo rates—will require prospective counseling at initiation and careful monitoring, particularly in patients with pre-existing overactive bladder. Full quantitative efficacy data from the FirstLight and RadiantLight trials have not yet been published in peer-reviewed form, and independent analysis of those results will be important for contextualizing the benefit-risk profile.

References

1. US Food and Drug Administration. FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms. News release. Augut
2. Barateau L, Dauvilliers Y. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:1756286419875622.
3. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654-2662.
4. Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9-27.
5. Takeda Pharmaceutical Company Limited. U.S. FDA approves Takeda's ORZEYFUL™ (oveporexton). BusinessWire. August 5, 2026. https://www.businesswire.com/news/home/20260805760759/en/U.S.-FDA-Approves-Takedas-ORZEYFUL-oveporexton-the-First-and-Only-Medicine-to-Treat-the-Underlying-Cause-of-Narcolepsy-Type-1